Ionis Pharmaceuticals, Inc. Other Comprehensive Income (Loss), Reclassification Adjustment for Sale of Securities Included in Net Income, Net of Tax (Deprecated 2013-01-31)
Ionis Pharmaceuticals, Inc. (IONS) reported Other Comprehensive Income (Loss), Reclassification Adjustment for Sale of Securities Included in Net Income, Net of Tax (Deprecated 2013-01-31) of -$1.16 million for the 6-month period ending 2013-06-30, per its 10-Q filed 2013-08-06.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentForSaleOfSecuritiesIncludedInNetIncomeNetOfTax · last filed 2013-08-06
- Ionis Pharmaceuticals, Inc. other comprehensive income (loss), reclassification adjustment for sale of securities included in net income, net of tax (deprecated 2013-01-31) for the quarter ending 2013-06-30 was $0.00.
- Ionis Pharmaceuticals, Inc. other comprehensive income (loss), reclassification adjustment for sale of securities included in net income, net of tax (deprecated 2013-01-31) for the quarter ending 2013-03-31 was -$1.16M.
- Ionis Pharmaceuticals, Inc. other comprehensive income (loss), reclassification adjustment for sale of securities included in net income, net of tax (deprecated 2013-01-31) for fiscal 2010 was $138.00K.
| Period end | Other Comprehensive Income (Loss), Reclassification Adjustment for Sale of Securities Included in Net Income, Net of Tax (Deprecated 2013-01-31) 3 month | Other Comprehensive Income (Loss), Reclassification Adjustment for Sale of Securities Included in Net Income, Net of Tax (Deprecated 2013-01-31) 6 month | Other Comprehensive Income (Loss), Reclassification Adjustment for Sale of Securities Included in Net Income, Net of Tax (Deprecated 2013-01-31) 12 month |
|---|---|---|---|
| 2013-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06 | -$1.16M 10-Q · filed 2013-08-06 | |
| 2013-03-31 | -$1.16M 10-Q · filed 2013-05-07 | ||
| 2010-12-31 | $138.00K 10-K · filed 2013-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |